Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Shire to participate at two upcoming investor conferences
Lexington, MA, USA - September 7, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the Bank of America Merrill Lynch Global Healthcare Conference 2017 on September 14, 2017 at 1:45 p.m. BST (8:45 a.m. EDT) and Jeff Poulton, Chief Financial Officer will participate at the Morgan Stanley Global Healthcare Conference on September 12, 2017 at 3:30 p.m. EDT (8:30 p.m. BST).
The live audio webcasts of both events will be available on Shire's Investor website at http://investors.shire.com/presentations-and-reports/quarterly-results-and-presentations. Subsequently, a replay of both events will be available on this same website
For further information please contact:
| Investor Relations | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 1256 894874 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
